3 Promising Penny Stocks With Market Caps Under $200M

Over the last 7 days, the market has remained flat, yet it is up 28% over the past year with earnings forecasted to grow by 16% annually. Penny stocks may be a throwback term, but they still offer intriguing opportunities for growth at lower price points, especially when backed by strong balance sheets and solid fundamentals. This article explores several penny stocks that stand out as hidden gems, potentially offering both stability and upside in today's market landscape.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
WM Technology (MAPS)	$0.36	$57.1M	✅ 3 ⚠️ 5 View Analysis >
LexinFintech Holdings (LX)	$2.045	$344.1M	✅ 3 ⚠️ 2 View Analysis >
FinVolution Group (FINV)	$4.85	$1.27B	✅ 4 ⚠️ 1 View Analysis >
Information Services Group (III)	$3.11	$196.42M	✅ 3 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.77	$382.78M	✅ 3 ⚠️ 1 View Analysis >
Cricut (CRCT)	$4.275	$897.31M	✅ 2 ⚠️ 2 View Analysis >
Village Farms International (VFF)	$2.82	$322.29M	✅ 5 ⚠️ 1 View Analysis >
SIGA Technologies (SIGA)	$7.80	$323.12M	✅ 2 ⚠️ 1 View Analysis >
BAB (BABB)	$0.90	$6.59M	✅ 2 ⚠️ 3 View Analysis >

Click here to see the full list of 349 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Nephros (NEPH)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nephros, Inc. is a commercial-stage company that develops and sells water filtration solutions for medical and commercial applications in the United States, with a market cap of $35.34 million.

Operations: The company's revenue is primarily derived from its water filtration segment, excluding pathogen detection, which generated $18.79 million.

Market Cap: $35.34M

Nephros, Inc. has demonstrated significant growth with earnings increasing by a very large percentage over the past year, exceeding industry averages. The company is debt-free and boasts high-quality earnings, with its short-term assets comfortably covering both short and long-term liabilities. Recent initiatives include expanding water safety support capabilities following new certifications and entry into the Puerto Rico market to address unmet needs in water filtration for healthcare and hospitality sectors. This strategic expansion could open new revenue streams through consulting services while enhancing customer value through comprehensive Water Management Programs.

• Dive into the specifics of Nephros here with our thorough balance sheet health report.
• Evaluate Nephros' prospects by accessing our earnings growth report.

Resources Connection (RGP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Resources Connection, Inc. operates under the Resources Global Professionals (RGP) name, providing consulting services to business customers across North America, the Asia Pacific, and Europe, with a market cap of $140.24 million.

Operations: The company's revenue is primarily derived from its On-demand Talent segment at $181.35 million, followed by Consulting at $174.12 million, Outsourced Services contributing $40.20 million, and operations in Europe & Asia Pacific generating $79.39 million.

Market Cap: $140.24M

Resources Connection, Inc. has faced challenges with profitability, reporting a net loss of US$9.47 million in Q3 2026, though this is an improvement from the previous year. The company remains debt-free with short-term assets significantly exceeding liabilities, providing financial stability despite ongoing losses. Recent leadership changes aim to bolster AI capabilities and expand consulting services across various segments including M&A and supply chain management. The dividend of US$0.07 per share reflects commitment to shareholder returns amidst strategic shifts aimed at leveraging technology for operational efficiency and client service enhancement within its consulting framework.

• Navigate through the intricacies of Resources Connection with our comprehensive balance sheet health report here.
• Gain insights into Resources Connection's future direction by reviewing our growth report.

Xtant Medical Holdings (XTNT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Xtant Medical Holdings, Inc. offers regenerative medicine products and medical devices for orthopedic and neurological surgeons both in the United States and internationally, with a market cap of $77.43 million.

Operations: The company generates $133.93 million in revenue from the development, manufacture, and marketing of orthopedic medical products and devices.

Market Cap: $77.43M

Xtant Medical Holdings has shown a transition to profitability, reporting net income of US$4.97 million for 2025 compared to a loss the previous year, supported by revenue growth to US$133.93 million. Despite this progress, earnings are expected to decline over the next three years. The company's debt management is prudent with a reduced debt-to-equity ratio and well-covered interest payments by operating cash flow. Recent strategic moves include acquiring exclusive U.S. distribution rights for Dilon Technologies' HEMOBLAST Bellows, enhancing its product portfolio amidst stable weekly volatility and experienced management oversight. However, interest coverage remains below optimal levels at 2x EBIT.

• Get an in-depth perspective on Xtant Medical Holdings' performance by reading our balance sheet health report here.
• Examine Xtant Medical Holdings' earnings growth report to understand how analysts expect it to perform.

Taking Advantage

• Click here to access our complete index of 349 US Penny Stocks.
• Ready To Venture Into Other Investment Styles? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com